- Home
- DNUT vs ESPR Comparison
DNUT vs ESPR Comparison
Compare DNUT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- ESPR
- Stock Information
- Founded
- DNUT 1937
- ESPR 2008
- Country
- DNUT United States
- ESPR United States
- Employees
- DNUT N/A
- ESPR N/A
- Industry
- DNUT Food Chains
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- ESPR Health Care
- Exchange
- DNUT Nasdaq
- ESPR Nasdaq
- Market Cap
- DNUT 563.2M
- ESPR 660.1M
- IPO Year
- DNUT 2021
- ESPR 2013
- Fundamental
- Price
- DNUT $4.16
- ESPR $2.65
- Analyst Decision
- DNUT Buy
- ESPR Buy
- Analyst Count
- DNUT 6
- ESPR 6
- Target Price
- DNUT $6.22
- ESPR $6.50
- AVG Volume (30 Days)
- DNUT 15.2M
- ESPR 5.7M
- Earning Date
- DNUT 11-06-2025
- ESPR 11-06-2025
- Dividend Yield
- DNUT 1.68%
- ESPR N/A
- EPS Growth
- DNUT N/A
- ESPR N/A
- EPS
- DNUT N/A
- ESPR N/A
- Revenue
- DNUT $1,534,272,000.00
- ESPR $303,802,000.00
- Revenue This Year
- DNUT N/A
- ESPR $18.83
- Revenue Next Year
- DNUT $0.45
- ESPR N/A
- P/E Ratio
- DNUT N/A
- ESPR N/A
- Revenue Growth
- DNUT N/A
- ESPR 2.83
- 52 Week Low
- DNUT $2.50
- ESPR $0.69
- 52 Week High
- DNUT $12.27
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- DNUT 61.24
- ESPR 47.45
- Support Level
- DNUT $3.46
- ESPR $2.42
- Resistance Level
- DNUT $4.50
- ESPR $2.99
- Average True Range (ATR)
- DNUT 0.43
- ESPR 0.18
- MACD
- DNUT 0.02
- ESPR -0.04
- Stochastic Oscillator
- DNUT 52.11
- ESPR 32.27
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.